News

Food & Health Angels backs EdiMembre's high-protein food platform

What's the deal? Food & Health Angels, a US investor network, has made an angel investment in EdiMembreDealroom has a profile for this one. Try Dealroom →, a startup whose technology turns protein isolates into foods where more than 80% of calories come from protein. The round was announced in November 2026.

What does EdiMembre do? Its Protein Micro-Architecting platform converts protein isolates — from mung bean, soy, or animal sources — into a protein-based dough, then uses wet-extrusion to shape it into familiar foods. The company says the process enables low-carbohydrate products without sacrificing taste or texture.

Why now? The rise of GLP-1 medications and consumer interest in better-for-you products are pushing demand for protein. EdiMembre says conventional methods struggle to meet that demand, breaking down starch and producing "grainy, brittle, or rubbery textures and off-flavors" when protein exceeds 50% of calories.

What's the endgame? The capital will support a 100 ton-per-year pilot manufacturing line, B2B product development contracts with global food brands, and an expanded intellectual property portfolio. CEO and co-founder Tim Olsen says the platform can produce a two-ingredient pasta delivering 48g of protein per serving.

Who's behind it? EdiMembre is a spinout of MilliporeSigmaDealroom has a profile for this one. Try Dealroom →, the life science business of Germany's Merck, built on five years and US$5 million in R&D. Annette Shafer, a Food & Health Angels investor, says the platform lets manufacturers "make higher-protein foods part of more people's everyday diets."

The signal: As GLP-1 users and health-conscious consumers reshape grocery aisles, investors are betting on formulation technology that can push protein content higher without the texture penalties that have limited the category.

Read more: nutritioninsight.com

Image credit: "Cooked - Sapore High Barley Fibre Natural Barley Fettuccine - US$1.62" by avlxyz, licensed under CC BY-SA 2.0

More top stories